IRIS Toxicological Review of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) (Interagency Science Consultation Draft)

Notice - This site contains archived material(s)

Archive disclaimer
Archive disclaimer
Archived files are provided for reference purposes only. These files are no longer maintained by the Agency and may be outdated. For current EPA information, go to www.epa.gov. It is EPA's policy to support reasonable accommodation to persons with disabilities, pursuant to the Rehabilitation Act of 1973, 29 U.S.C. 791. If you need assistance with accessing archived files, contact EPA's Reasonable Accommodations or submit a request using the Contact Us form.


Abstract

On March 10, 2016, the public comment draft Toxicological Review of Hexahydro-1,3,5-trinitro-1,3,5-triazine and the draft charge to external peer reviewers were released for public review and comment. The Toxicological Review and charge were reviewed internally by EPA and by other federal agencies and White House Offices before public release. Consistent with the May 2009 IRIS assessment development process, all written comments on IRIS assessments submitted by other federal agencies and White House Offices are made publicly available. Accordingly, interagency comments and the interagency science consultation materials provided to other agencies, including interagency review drafts of the IRIS Toxicological Review of Hexahydro-1,3,5-trinitro-1,3,5-triazine and the charge to external peer reviewers, are posted on this site.

Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX, or Royal Demolition eXplosive) is a military explosive with limited civilian uses. In the United States, RDX is produced at Army ammunition plants; it is not produced commercially.

An oral reference dose (RfD) and an oral cancer slope factor are currently available on IRIS. A reassessment of the human health effects of RDX, including both cancer effects and effects other than cancer, is being undertaken.

Impact/Purpose

EPA is undertaking an update of the Integrated Risk Information System (IRIS) health assessment for RDX. The outcome of this project is an updated Toxicological Review and IRIS Summary for RDX that will be entered into the IRIS database.

Status

The hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) IRIS assessment was released for public comment in March 2016. Following the public comment period, the assessment will be revised taking into consideration public comments. The assessment will then be released for external peer review.

Citation

U.S. EPA. IRIS Toxicological Review of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) (Interagency Science Consultation Draft). U.S. Environmental Protection Agency, Washington, DC, EPA/635/R-14/302, 2014.

History/Chronology

Date Description
01-Aug 2013EPA released preliminary draft materials for discussion at the December IRIS Bimonthly Public Meeting.
02-Dec 2013EPA discussed preliminary draft materials at the December 12-13, 2013 IRIS Bimonthly Public Meeting. Presentations are also available on the meeting web site.
03-Sep 2014EPA initiated the interagency science consultation on the draft Toxicological Review of RDX.
04-Mar 2016EPA released the public comment draft for a 60-day review period and announced it will be discussed at the May 10, 2016 IRIS Public Science Meeting. EPA also released the interagency science consultation documents, comments from reviewers, and EPA's response to major comments. [Federal Register Notice: Mar 10, 2016]

This download(s) is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy.


Related Link(s)